We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+9.51%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,043.31%
AUM
$470M
AUM Growth
+$131M
(+38%)
Cap. Flow
+$31.7M
Cap. Flow % of AUM
Cap. Flow %
6.73%
Top 10 Holdings %
Top 10 Hldgs %
48.76%
Holding
67
New
21
Increased
15
Reduced
13
Closed
12
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSRO
Tesaro
TSRO
|
+$15.9M |
| 2 |
Invesco CurrencyShares Swiss Franc Trust
FXF
|
+$12.3M |
| 3 |
ECYT
Endocyte
ECYT
|
+$10.3M |
| 4 |
ZGNX
Zogenix
ZGNX
|
+$10.2M |
| 5 |
Travere Therapeutics
TVTX
|
+$10M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mersana Therapeutics
MRSN
|
+$10.7M |
| 2 |
GBT
Global Blood Therapeutics
GBT
|
+$10.2M |
| 3 |
Arrowhead Research
ARWR
|
+$9.5M |
| 4 |
IMMU
Immunomedics
IMMU
|
+$8.67M |
| 5 |
Exelixis
EXEL
|
+$8.61M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.85% |
| 2 | Miscellaneous | 20.15% |
Similar funds
AFS
E
Ghost Tree Capital's Q3 2018 Portfolio in Review
As of Q3 2018, Ghost Tree Capital held 67 positions worth $470M, up 38% from $340M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital deployed $31.7M of net new capital in Q3 2018, opening 21 new positions and adding to 15 existing holdings. Its largest new stake was Tesaro: 450,000 shares worth $17.6M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Global Blood Therapeutics, an estimated $10.2M trimmed.
- Ghost Tree Capital's largest Q3 2018 buy was Tesaro: 450,000 shares worth $17.6M.
- Ghost Tree Capital added most to Endocyte in Q3 2018, an estimated $10.3M increase.
- Ghost Tree Capital's biggest Q3 2018 reduction was Global Blood Therapeutics, cutting an estimated $10.2M.
- Ghost Tree Capital fully exited Mersana Therapeutics in Q3 2018, selling an estimated $10.7M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $470M portfolio in Q3 2018.
- Ghost Tree Capital opened 21 new positions and closed 12 in Q3 2018.
- Ghost Tree Capital's portfolio value rose 38% quarter-over-quarter to $470M.
Based on Ghost Tree Capital's 13F filing for Q3 2018, filed 14 Nov 2018.